N/A
N=19,554
COVID-19 Vaccine Text Outreach
Covid19
Bottom Line
View on ClinicalTrials.gov: NCT04834726 ↗Enrolled (actual)
19,554
Serious AEs
—
Results posted
Mar 2023
Primary outcome: Primary: Dose 1 Completion — 14; 243; 253 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Opt-In (Call-Back) (Behavioral); Opt-in (In-Bound) (Behavioral); Standard Message (Behavioral); Clinician Endorsement (Behavioral); Scarcity (Behavioral); Opt-Out Framing (Behavioral); Phone Call (Behavioral)
- Age
- Pediatric, Adult, Older Adult · 16+ yrs
- Sex
- All
- Sponsor
- University of Pennsylvania
- Primary completion
- Jun 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Dose 1 Completion |
16; 315; 342 | — |
| SECONDARY Dose 1 Completion |
16; 315; 342 | — |
| SECONDARY Vaccine Completion |
13; 222; 231 | — |
Summary
This project aims to evaluate different approaches to increase COVID-19 vaccine uptake among at-risk patients at Penn Medicine in an equitable and systematic manner through a centralized outreach program. The investigators will evaluate different text-based scheduling and messaging approaches informed by behavioral science to increase uptake among eligible patients, including the use of clinician endorsement, opt-out framing, and scarcity.
Eligibility Criteria
Inclusion Criteria
- patients of Penn Medicine aged 18+ who reside in Philadelphia and who have had at least 1 visit in the past 5 years with a Penn Medicine primary care provider (PCP)
Exclusion Criteria
- Patients who have completed any dose of the vaccine at Penn Medicine, are currently scheduled to receive the vaccine, have externally documented vaccination records, or have previously received text-message based vaccine outreach.
Data sourced from ClinicalTrials.gov (NCT04834726). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.